Bob Young MMSc, MD, FRCP

• Consultant Diabetologist
• Diabetes Centre
• Salford Royal Hospital
• Salford, UK

Explanations for this observed late benefit of nicotinic acid on mortality include the early decreases in incidence of nonfatal reinfarction and the cholesterol-lowering effects of nicotinic acid on the coronary arteries erectile dysfunction books cheap silvitra 120 mg online. Nearly 30% of the men in the nicotinic acid group adhered poorly to the treatment regimen (took less than 60% of the amount of drug called for by the protocol) erectile dysfunction talk your doctor order silvitra 120 mg amex, yet there was a significant benefit in 15-year mortality erectile dysfunction remedies fruits order silvitra in india. This suggests that less than optimal doses of nicotinic acid may nevertheless result in therapeutic benefits erectile dysfunction treatment side effects order 120 mg silvitra fast delivery. Both groups received advice regarding diet impotence vitamins generic silvitra 120 mg mastercard, and the treatment group received both drugs as above. Subjects in the treatment group exhibited mean reductions in total serum cholesterol and serum triglycerides of 15% to 20% and 30%, respectively. However, over a 4-year period, the number of nonfatal reinfarctions in the treatment group was reduced by 50% compared with the control group. In comparison, the Coronary Drug Project reported a 27% reduction in nonfatal reinfarctions in the nicotinic acid group and insignificant reductions in the clofibrate group. Nicotinic acid has been found to decrease lipolysis in adipose tissue, resulting in decreased levels of plasma free fatty acids. In fact, 61% of the treatment group subjects improved or remained the same, and 16. Regarding native vessels, treatment reduced the average number of lesions that progressed per subject and the percentage of subjects with new lesions. In contrast, 10 cardiovascular events occurred in the control group, 46% of patients showed regional progression, and 11% showed regression of coronary lesions. Patients with disease, a family history of premature cardiovascular events, and elevated levels of apo B (3. Favorable changes in clinical course and lesion severity appeared with the combination regimens. The results of a blinded, placebo-controlled larger (160 patients) angiographic regression trial of combination therapy were recently reported. Combined antioxidant therapy significantly blunted the benefit of the drug regimen, both on plasma lipids and on angiographic progression. The endpoint was reached in 24% of the placebo-treated patients, 21% of the patients given antioxidants alone, 14% of those given both, and 3% of those given simvastatin and niacin alone. The negative effect of combining vitamins with drug therapy cannot be considered established given the modest size and statistical power of this study. However, any benefits of vitamins alone on angiographic disease did not reach statistical significance and were not correlated with any effect on clinical endpoints. Recently, the drug was shown to have an advantage over ezetimibe on the progression of atherosclerosis. It is important to remember that a diet low in cholesterol and saturated fats is the foundation of therapy for hyperlipoproteinemia. The drug is indicated for use in combination with lovastatin and simvastatin, and combination formulations are available. Nicotinic acid is available in 100, 125, 250, and 500 mg tablets as well as in a time-release form. Therapeutic effects of the drug are usually not manifest until the patient reaches a total daily dose of at least 3 g. A greater response may be attained with periodic increases in doses up to a maximum of 7 to 8 g daily, although the incidence of adverse effects also increases with higher doses. In general, it is best to use the lowest dose necessary to achieve the desired alterations in plasma lipoprotein levels. Nicotinic acid therapy should be initiated with a lowdosage regimen (100 mg daily), gradually increasing the dose every few days over a period of several weeks until the patient attains a dosage level of 3 g daily given in 3 divided doses. If, while increasing the dose, the patient develops any adverse effects, the dose should be cut back and then resumed at a more gradual pace. It is interesting that tachyphylaxis to the flushing phenomenon often occurs within a few days,8 although the bothersome episodes may recur if the patient misses 2 or 3 doses. If the therapeutic effects are unsatisfactory, the dose should be increased by a further 1. Usually, when doses of 4 g daily are achieved, another lipid-lowering drug is added. Regardless of the dose, it is important to make several laboratory evaluations for potential adverse effects at regular intervals. These include assessment of liver function (bilirubin, alkaline phosphatase, and transaminase levels), uric acid levels, and serum glucose levels. The drug may also impair glucose tolerance and is contraindicated in patients with diabetes mellitus that is difficult to control. Nicotinic acid is also associated with reversible elevations of liver enzymes and uric acid and should not be used in patients with hepatic disease or a history of symptomatic gout. A proprietary "intermediate release" formulation of nicotinic acid (Niaspan) that requires a prescription is also suitable for once-daily administration. Some studies have experienced as much as a 50% dropout rate as a result of drug-related adverse effects. The mechanism of the flushing is presumed to be related to the effect of nicotinic acid on vasodilatory prostaglandins and is frequently attenuated by pretreatment with aspirin. This vasodilatory effect in combination with antihypertensive therapy may potentially result in postural hypotension. The Coronary Drug Project also described an increased incidence of atrial fibrillation; other transient cardiac arrhythmias were noted. Some studies have also noted elevations in bilirubin, occasionally leading to jaundice. The elevations in transaminases are generally transient and reverse with decrease in dosage or cessation of therapy; these elevations can be minimized by increasing the dosage in gradual increments when therapy is being initiated. Several cases of niacin hepatitis progressing to fulminant hepatic failure have been described, most frequently with the time-release formulation, with biochemical, clinical, and histologic evidence of hepatocellular injury. In most cases, cessation of therapy leads to eventual resolution of abnormalities. Hyperglycemia and impaired glucose tolerance may occur with nicotinic acid therapy and often necessitates adjustments in diet and hypoglycemic therapy in diabetic patients. The results of a recent study demonstrated that niacin is an effective treatment for hyperlipidemia in patients with diabetes mellitus and that its adverse effects on glycemic control are modest. The drug is, therefore, potentially useful for the management of all types of hyperlipoproteinemia except type I; however, untoward adverse reactions must be carefully monitored. Cholesterol Absorption Inhibitor-Ezetimibe Pharmacology Ezetimibe is the first drug to be approved for clinical use in this novel class of lipid-lowering agents (the 2-azetidinones), known as selective cholesterol absorption inhibitors. This action causes a reduction of hepatic cholesterol stores and increase in clearance of cholesterol from the blood. Ezetimibe and its metabolite are eliminated slowly from the plasma, with a half-life of approximately 22 hours for both, with their excretion mostly in stool. Conclusion Nicotinic acid is a second or third choice for isolated hypercholesterolemia because of the troublesome adverse effects associated with the drug. In clinical trials, the overall incidence of adverse effects reported with ezetimibe was similar to that reported with the placebo, and the discontinuation rate due to adverse effects was similar. The adverse experience rates were similar between ezetimibe with various statins and statins used alone. However, the frequency of increased transaminases was slightly higher in patients receiving ezetimibe administered with statins than with statins alone. With combination therapy, it is recommended that liver function tests be performed at the initiation of therapy and according to the recommendations of the particular statin being used. Ezetimibe is not recommended in patients with moderate or severe hepatic insufficiency and should not be used in pregnancy. There has been no excess in myopathy or rhabdomyolysis associated with ezetimibe monotherapy or combination with statins. The drug has no significant effects on medications metabolized by cytochrome P450 and is neither an inhibitor nor an inducer of cytochrome P450. No dose adjustments are necessary in the elderly or for patients with mild renal and hepatic insufficiency. Concomitant cholestyramine administration decreases the plasma levels of ezetimibe by 50%. The drug is also approved for clinical use in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments and for patients with homozygous sitosterolemia as adjunctive therapy to diet. The drug can be taken with or without food, and can be administered with statins at the same time. The co-administration of ezetimibe with fibrates is not recommended because the safety and effectiveness of this combination has not been established. Studies are in progress investigating whether ezetimibe will reduce cardiovascular events. Many other brands of fish oil capsules are sold over the counter as dietary supplements without any regulation of their content or purity. A current question that has yet to be fully answered is whether estrogen is more effective for primary prevention or for treating atherosclerosis once it is already established. Potential mechanisms include inhibition of acyl CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal beta oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. There are no interactions with statins to cause rhabdomyolysis, unlike gemfibrozil. The natural gel-forming fibers (pectins, gums, mucilages, and the rest of the hemicelluloses) are soluble in humans. Both soluble and insoluble fibers cause an increased bulk of softer stool due to their increased water-retaining capabilities. In addition, soluble fibers retard gastric emptying and decrease food absorption and digestion. In various experimental studies, soluble fibers such as pectin, guar gum, oat bran, and psyllium have also been shown to reduce blood cholesterol levels. This may simply relate to the correlation of increased insoluble dietary fiber with increased vegetable protein, which may be the actual therapeutic agent. Its effectiveness relates to its ability in delivering 5 times more soluble fiber than oat bran and its ease of administration as a dietary supplement to patients with hypercholesterolemia. Psyllium is a soluble gel-forming fiber derived from the husks of blond psyllium seeds of the genus Plantago, plants grown in the Mediterranean region and in India. The processing of psyllium involves the initial separation of the seeds from the plant husks and then grinding the husks to make the final psyllium substance. The seed husk is then enriched with mucilloid, a hydrophilic substance that forms a gelatinous mass when mixed with water. The polysaccharide fraction is the active one and is made of 63% D-xylose, 20% L-arabinose, 6% rhamnose, and 9% D-galacturonic acid, as derived by acid hydrolysis and methylation analysis. Structural features of this component are those of a highly branched acidic arabinoxylan: xylan backbone with sugar 1:4 and 1:3 linkages. It is the universal impression from clinical trials that psyllium is a hypocholesterolemic agent531 with and without a modified diet. The chemical components of naturally occurring dietary fiber include cellulose, lignins, hemicelluloses, pectins, gums, and mucilages. Dietary fibers can be classified in to 2 major groups based on their water-solubility. Available information suggests that one or more of the following mechanisms may be operative. First, psyllium has been shown to prevent the normal reabsorption of bile acids in the gut. Second, soluble fibers such as psyllium may interfere with micelle formation in the proximal small intestine, resulting in decreased absorption of cholesterol and fatty acids. These fatty acids (predominantly propionate and acetate) are rapidly absorbed in to the bloodstream and may inhibit hepatic cholesterol synthesis. A possible reason for the acceptability of psyllium therapy is that patients will have well-formed stools and a low incidence of adverse effects. Some patients placed on psyllium report abdominal distention, excessive gas, and flatulence, but these symptoms usually subside after a few weeks. Some studies have revealed an effect of psyllium on the binding of sodium warfarin. Any potential problem can be avoided by separating the intake of psyllium and drug by 1 to 2 hours. Finally, patients with congestive heart failure may be at risk from an excessive salt load with psyllium ingestion. The phase I diet in the treatment of hypercholesterolemia consists of no more than 300 mg of dietary cholesterol per day, with a maximum 30% total energy as fat. With the addition of fiber, the cholesterol-lowering effect of this diet can be improved significantly. The efficacy of psyllium in lowering cholesterol is consistent with that of many other soluble fibers. Studies have found that, in contrast to oat bran, 15 g of pectin added to the diet lowered cholesterol by an additional 11%. It is concluded that psyllium is useful as an adjunct to dietary therapy in the treatment of patients with mild to moderate hypercholesterolemia. However, combining psyllium with the other drug treatments for lowering cholesterol appears to be quite useful. Despite this structural relation to cholesterol, it is poorly absorbed from the intestine. Another plant sterol, -sitostanol, reduces serum cholesterol more effectively than sitosterol at a lower dose. Fiber supplementation is widely accepted as part of achieving a healthful diet in adults and children. Lifibrol Lifibrol is a novel lipid-lowering agent with an unknown mechanism of action.

Syndromes

• Measurement of concentration of tears (osmolalilty)
• Diabetes
• Head nodding
• Urinalysis
• Intentional overdose
• Get rid of extra fluids
• Liver damage from poisoning or medications

A rare genetic disorder impotence 2 discount 120 mg silvitra with amex, Birt­Hogg­ Dubé syndrome erectile dysfunction injection buy silvitra in india, may cause spontaneous pneumothorax in families as a result of lung cyst formation (Menko et al impotence remedies silvitra 120 mg amex. Catamenial pneumothorax (occurring in relation to the menstrual cycle) with endometriosis in the chest may be found in adolescent females (Johnson erectile dysfunction wellbutrin xl discount silvitra 120 mg fast delivery, 2004; Joseph & Sahn erectile dysfunction use it or lose it discount silvitra 120 mg line, 1996). Pathophysiology Air leak through the visceral and/or parietal pleura results in pneumothorax. These pressure differences typically occur with increases in alveolar pressure such as during positive pressure ventilation or Valsalva maneuver, or with more negative intrapleural pressure such as with severe asthma exacerbation. Subpleural blebs, when present, are usually found in the apices of the lungs due to the difference in transalveolar pressure between the apices and the bases of the lungs (West, 2007; Jenkinson, 1985). Occasionally, blebs can rupture in to other anatomical spaces such as the mediastinum, soft tissues, and peribronchial tissues leading to pneumomediastinum, subcutaneous emphysema, and pulmonary interstitial emphysema, respectively. Pneumothorax could also occur as a result of direct injury to the visceral pleura. Bronchopleural fistula may occur as a result of a persistent connection between the airways and pleural space. The Acute respiratory problems 295 air leak is eventually resorbed without any interventions. When the pneumothorax is large, the buildup of pressure in the intrapleural space leads to lung collapse. The significantly increased intrapleural pressure shifts the mediastinum away from the affected side, leading to compromised venous return, decreased ventricular size during diastole, decreased cardiac output, and cardiovascular collapse (Leigh-Smith & Harris, 2005; Montgomery, 2006). The signs and symptoms of a pneumothorax may be attenuated by preexisting adhesions in the pleural space. Despite its size, lung collapse and the accompanying effects of a tension pneumothorax may not occur when the visceral pleura is tethered to the parietal pleura due to the adhesions. Signs and symptoms the signs and symptoms of a pneumothorax may be subtle with nonspecific chest pain or vague symptoms of feeling uncomfortable, or may present with acute respiratory distress with cardiopulmonary compromise. The clinical presentation depends on a number of factors including the size of the pneumothorax (amount of air leak in the pleural space), the degree of lung collapse, the speed of equilibration (rapid vs. History Sudden onset of chest pain and dyspnea is the usual complaint of a patient with a large pneumothorax. The pain is described as sharp or stabbing, and can even be preceded by a sensation of "popping" on the affected side. The pain typically is diffuse on the affected side with radiation to the ipsilateral shoulder. A small pneumothorax may present with minimal to no symptoms and may be an incidental finding on a chest imaging for another indication. Patients presenting with spontaneous pneumothorax should always be investigated for potential underlying conditions that may predispose them to develop the pneumothorax. Physical examination Physical findings associated with a large pneumothorax may include decreased breath sounds, decreased chest rise during inspiration, and hyperresonance on percussion on the affected side. Respiratory compromise may include tachypnea, increased work of breathing, and cyanosis. Patients should be examined for signs of tension pneumothorax, such as tracheal shift to the opposite side, decreased heart sounds, and apical impulse shifted to the opposite side. Crepitations usually imply the 296 Nursing Care in Pediatric Respiratory Disease presence of subcutaneous emphysema and can be palpitated on the chest wall and the neck. Both anteroposterior and lateral views will be helpful in delineating the pleural air especially for the small pneumothorax. A large pneumothorax presents with more obvious findings including a hyperlucent area surrounding the collapsed lung on the affected side, flattening of the diaphragm on the affected side, and tracheal and/or mediastinal shift to the opposite side of the pneumothorax. A lateral decubitus film with the affected side up may also be helpful, especially in an infant. In newborns, transillumination of the chest in a darkened room may help make the diagnosis of pneumothorax immediately, especially in an emergency. A high-intensity fiber-optic probe is placed against the chest wall of the neonate. Positive transillumination is highly suggestive of a pneumothorax (Kuhns, Bednarek, Wyman, Roloff, & Borer, 1975). In adults, recurrence of spontaneous pneumothorax is about 30% (Kirby & Ginsberg, 1992; Paape & Fry, 1994). Reports in children are limited (Davis, Wensley, & Phelan, 1993; Wilcox, Glick, Karamanoukian, Allen, & Azizkhan, 1995). In a report of 58 children with spontaneous pneumothorax, the risk of recurrence was 50%, with each recurrence increasing the risk of further recurrences (Poenaru, Yazbeck, & Murphy, 1994). Activities associated with drastic changes in pressure like scuba diving and flying in unpressurized aircrafts should be avoided to decrease recurrence. In addition, patients are advised to avoid contact sports, playing wind musical instruments, or air travel at least 4 weeks after an episode of pneumothorax (Montgomery, 2006). Management Management depends on the severity of symptoms, size of the pneumothorax, and the underlying lung problem. Note the pleural line (white line) outlining the visceral pleura on the left apex with a small area of hyperlucency with no lung and vascular markings (as compared to the rest of the lung fields). There is also the presence of pneumomediastinum, with note of air (black line) outlining the mediastinal area. Treatment of the underlying lung disease, if any is identified, should be addressed. Unless the patient is inhaling supplemental oxygen when the pneumothorax occurred, air in the intrapleural space is room air with 21% oxygen and 79% nitrogen. Inhalation of 100% oxygen creates a steep gradient for nitrogen absorption from the intrapleural space in to the alveolar space. Eventually, the air in the intrapleural space gets converted in to 100% oxygen, which is more easily resorbed by the body compared with nitrogen. Oxygen at 100% can only be delivered to a nonventilated patient via a non-rebreather mask. Needle aspiration and chest tube placement are options for evacuation of the pleural air (Camuset et al. In an emergency, air can be evacuated from the intrapleural space with a large-bore intravenous catheter placed anteriorly in the second intercostal space of the affected site. The catheter can be connected to a large syringe via a three-way stopcock or to a tubing with the opposite end submerged in water. If the latter method is used, where the tubing is submerged in water, bubbles should form until the pneumothorax is completely evacuated. The temporary catheter is typically converted in to a chest tube (pigtail catheter or thoracostomy tube) until the source of the air leak is identified and addressed or no more air leak is present. The chest tube uses a one-way Heimlich valve or water seal device to prevent reaccumulation of air. Suction is applied to a water seal device if the lung does not fully expand after the drainage. The chest tube is usually clamped when no bubbles are seen on the water seal from the patent tube after approximately 12 hours. The chest tube is then removed after 24 hours if there is no radiographic or clinical evidence of recurrence of the pneumothorax. Pleurodesis Pleurodesis is the injection of sclerosing agents at the time of thoracostomy tube placement to decrease the risk of recurrence. In a report of about 200 spontaneous pneumothorax cases, the recurrence rate in the intrapleural tetracycline group (25%) was significantly less than that in the control group (41%)(Light et al. Acute respiratory problems 299 Surgical intervention Surgery is indicated for persistent air leaks and is needed more often in secondary rather than in primary pneumothorax. Thoracoscopic treatment of spontaneous pneumothorax is safe and effective in children. Surgical intervention includes stapling or oversewing of ruptured blebs or tears, and resection of abnormal lung tissue, if found. Nursing care of the child and family Nursing care of the child with a pneumothorax requires a comprehensive understanding of normal respiratory anatomy and physiology in order to understand the process that led to the accumulation of air in the pleural space and the rationale for the treatment in an individual patient. Needle aspiration or chest tube placement may be needed to remove the air, restore negative pressure, and re-expand the lung. Once a chest tube is placed, the nurse should consult with the medical team to confirm that a chest X-ray was performed and should document proper placement of the tube. In the event of tube displacement, the site should be covered with a sterile petroleum dressing to prevent ambient air from entering the pleural space and from enlarging the pneumothorax. Furthermore, if the tube becomes disconnected, place the end of the tube in a bottle of sterile water until a new unit is established (Verger & Lebet, 2008). When treating a small pneumothorax with 100% supplemental oxygen, the nurse must ensure that the non-rebreather mask is maintained in place and that it has adequate flow from the oxygen flow meter. Nursing care of the patient with a chest tube includes managing and monitoring the chest tube system function. A chest tube is connected to a drainage system and the specific system used varies according to the institution. The amount of sterile water in the water seal chamber and negative pressure are dictated by the manufacturer. The tubing should be kept in a dependent position free of loops that could impede the evacuation of air. Milking or stripping chest tubes causes large 300 Nursing Care in Pediatric Respiratory Disease fluctuations in intrapleural pressure and may cause air leak, bleeding from entrapment of pleural tissue in the drainage system, or worsening of the pneumothorax (Halm, 2007). The integrity of the suture made at the time of tube placement should be assessed. Assessment includes observing the insertion site for signs of infection such as redness, swelling, warmth, and drainage (color and amount). An occlusive petroleum dressing is applied to the insertion site to prevent air leaks. All patients with pneumothorax require continuous cardiopulmonary and pulse oximetry monitoring. The nurse must monitor vital signs and respiratory status including auscultation of breath sounds in all lung fields. Signs of a tension pneumothorax include tachycardia, hypotension, dyspnea, chest pain, decreased oxygen saturation, and tracheal deviation (a relatively late finding). Nursing care of patients with a pneumothorax also includes regular encouragement of deep breathing and position changes. Pain management should be ongoing to prevent the child from splinting (especially during coughing or deep breathing), which could prevent optimal lung re-expansion. As children are recovering from a pneumothorax, education should be provided cautioning patients against certain activities. Children should avoid flying, contact sports, scuba diving, and playing musical wind instruments. Therefore, it is very important to be able to recognize early signs immediately and to intervene appropriately. There are several anatomical and physiological differences in the respiratory system in infants and younger children as they develop. These differences may explain the higher incidence of respiratory failure in the younger age group. The upper airway is funnel shaped, with its narrowest portion at the subglottic area. Respiratory failure occurs when the respiratory system cannot sustain adequate gas exchange, particularly oxygen and carbon dioxide. Even with significant impairment in gas exchange, children may be clinically stable until rapid deterioration happens. High-risk children with chronic respiratory insufficiency (as seen in neuromuscular disease) may have acute deterioration during an intercurrent respiratory infection. Epidemiology Respiratory failure can be caused by abnormalities of one or any combination of the following three main categories: (1) (2) (3) Central nervous system (respiratory drive) Chest wall and respiratory muscles (respiratory pump) Lungs (gas exchange) the representative causes of respiratory failure in children categorized in to the three main areas are shown in Table 11. Twothirds of the cases in children occur in the first postnatal year, and one-half is seen in the neonatal period (Nitu & Eigen, 2009). Pathophysiology Respiratory failure occurs when there is derangement in oxygenation and/ or ventilation. For oxygen to be used by the tissues, it needs to enter the alveoli from the atmosphere. Oxygen binds to hemoglobin and is transported to the tissues for use by the cells. It may involve the whole body (generalized 302 Nursing Care in Pediatric Respiratory Disease Table 11. Representative causes of respiratory failure in children categorized in three main Disorders of the central nervous system (respiratory drive) Head trauma Toxic ingestion Congenital hypoventilation syndrome Apnea of prematurity Disorders of the chest wall and respiratory muscles (respiratory pump) Neuromuscular disease (myopathies/muscular dystrophies) Spinal cord injury Respiratory muscle fatigue during an acute respiratory infection in a previously healthy infant Disorders of the lungs (gas exchange) Asthma Bronchiolitis Pneumonia hypoxia) or a region of the body (tissue hypoxia). The most frequent cause of hypoxemia is an imbalance of ventilation (V) and perfusion (Q) or V/Q mismatch. Ventilation refers to the air that reaches the lungs, while perfusion refers to the blood that reaches the lungs. The V/Q ratio is a measure of the efficiency and adequacy of the matching between these two variables. If there is no ventilation but blood continues to perfuse the lungs, a shunt exists. If there is no blood flow but air continues to ventilate the lungs, dead space ventilation exists. A shunt leads to hypoxemia, while dead space ventilation leads to hypercarbia in the absence of compensation. Shunts may be intrapulmonary such as in areas of atelectasis where blood continues to perfuse the collapsed lung areas. Shunts may also be intracardiac as in tetralogy of Fallot, where blood from the right ventricle bypasses the lungs through the ventricular septal defect.

When norepinephrine is administered exogenously erectile dysfunction university of maryland order silvitra 120 mg otc, its major action is to stimulate alpha1 receptors erectile dysfunction hypertension medications silvitra 120 mg buy amex, leading to marked peripheral arterial vasoconstriction erectile dysfunction inventory of treatment satisfaction edits silvitra 120 mg overnight delivery. Thus erectile dysfunction medication south africa best buy for silvitra, norepinephrine has been used to reverse severe hypotension in order to preserve blood flow to vital organs erectile dysfunction treatment doctors in bangalore cheap silvitra 120 mg online. Continued administration of norepinephrine may produce ischemic renal damage due to sustained renal vasoconstriction. For the failing heart, this peripheral vasoconstriction also provides an undesirable added pressure load (afterload) and altered oxygen consumption,63 which tends to vitiate the potential benefits of beta1 stimulation. Dopamine62 has alpha1 and beta1 activity but also stimulates dopaminergic receptors in the renal vasculature to produce arterial dilation and increased renal blood flow. Its beta1 effects in the heart occur largely through the release of endogenous norepinephrine, which may be largely depleted in the failing heart. As doses of dopamine are increased, conversion to norepinephrine also occurs, which tends to produce relatively more pressor effects than myocardial inotropic stimulation. Low-dose dopamine can also be used in combination with norepinephrine to blunt norepinephine-induced renal vasoconstriction. However, dopamine was associated with more cardiac arrhythmias and with a higher mortality rate among patients with cardiogenic shock. Since arterial pressure also rises modestly, peripheral vascular resistance must of necessity fall. The positive inotropic activity of dobutamine is mediated by direct stimulation of beta1 adrenergic receptors in the myocardium (Tables 13-2 and 13-3). The increased arterial pressure resulting from enhanced cardiac output may increase baroreceptor activity and thereby offset the rise in heart rate induced by beta-adrenergic stimulation. In the presence of severe hypotension, the beta2 stimulation of dobutamine may be harmful, and administration of an alpha1-stimulating vasoconstrictor such as norepinephrine or a higher dose of dopamine may also be necessary in order to increase arterial peripheral resistance. The major adverse effects of dobutamine are an excessive increase in heart rate with high rates of infusion and ventricular arrhythmias, both of which may mandate dose reduction and even drug discontinuation. In general, once hemodynamic benefits are attained, dobutamine is slowly withdrawn. In some cases this has not been possible, and sustained administration becomes necessary, which may require portable pumps for administration. Nevertheless, episodes of acute decompensation may intervene, characterized by increased pulmonary congestion and edema as well as reduced renal function with increasing fluid accumulation. Hormones such as glucagon activate the system and can increase myocardial contractility 198 Cardiovascular Pharmacotherapeutics acutely despite beta1 blockade. For the time being, this has vitiated clinical study of these agents, but more stringent control of the use of this class of agents as adjuncts to other agents may ultimately increase their value. Initiation of milrinone therapy with a loading bolus has the advantage of producing immediate hemodynamic improvement. However, the loading bolus may precipitate atrial or ventricular arrhythmias and/or systemic hypotension. The rapid onset of the direct relaxant effect of milrinone on the pulmonary vasculature is well suited to test pulmonary vascular reactivity. In contrast to nitroprusside and nitric oxide, which also decrease pulmonary vascular resistance, milrinone does not affect the transpulmonary pressure gradient. The milrinone-induced increase in cardiac output presumably lowers pulmonary vascular resistance by recruiting accessory vessels in the pulmonary circulation as well as flow-mediated pulmonary vasodilatation. Attempts have also been made to use milrinone to increase the tolerability of beta-blocker initiation by counteracting the myocardial depressant action of catecholamine withdrawal. In vitro, it demonstrated significant effects on cytokine production which may theoretically account for some of its observed clinical benefits. These metabolites are likely to prolong the hemodynamic effects of levosimendan after disappearance of the parent drug. Hemodynamic effect of levosimendan was demonstrated with a dose-response relationship with increases in cardiac output and stroke volume, and decreases in pulmonary capillary wedge pressure. However, the relative dose responses of the inotropic and vasodilating actions of enoximone and milrinone differ. At low doses, enoximone exhibits a more balanced inotropic and vasodilator effect than does milrinone. Intravenous levosimendan was bolused at 6 g/kg followed by a continuous infusion started at a rate of 0. Levosimendan caused dose-dependent increases in stroke volume (28%) and cardiac index (39%) that were sustained from the completion of the titration to 6 hours, without a significant increase in heart rate. There was a dose-dependent decrease in pulmonary capillary wedge, right atrial, pulmonary arterial, and mean arterial pressures. In a continuation of the trial published separately, the investigators found that the hemodynamic effects of levosimendan were sustained with continuous infusion of up to 48 hours and that after terminating a 24-hour infusion, the hemodynamic effects were sustained for at least another 24 hours. An initial loading dose of levosimendan of 24 g/ kg was infused over 10 minutes, followed by a continuous infusion of 0. Dobutamine was infused for 24 hours at an initial dose of 5 g/kg/ min without a loading dose with an option to increase the dose if an inadequate response was seen. An adequate response was defined as an increase in cardiac output of at least 30%. The primary endpoint (proportion of patients with hemodynamic improvement as defined by cardiac index increase > 30% and decrease of > 25% in pulmonary capillary wedge pressure at 24 hours) was achieved in 28% of levosimendan-treated patients and 15% of dobutamine-treated patients (P =. Clinical symptoms of dyspnea and fatigue improved to a greater, although nonsignificant, extent in the levosimendan group than in the dobutamine group. Termination of the infusion led to a rapid loss of the effects of dobutamine (<6 hours), but not those of levosimendan. In addition, there was a lower mortality in the levosimendan group at both 30 days (8% versus 17%; P =. There were no differences among the groups with respect to changes in dyspnea or fatigue. In the worst-rank analysis, patients treated with levosimendan were judged to have experienced worsening dyspnea and fatigue less frequently. However, there were more episodes of hypotension, atrial fibrillation, and ventricular ectopy as well as a nonsignificant increase in deaths at 14-90 days (15. Brain natriuretic peptide was significantly decreased at 24 hours in the levosimendan-treated patients as compared to dobutamine-treated patients (-631 vs. However, all-cause mortality over 180 days was similar in the levosimendan and dobutamine arms (26. Similarly, there were no differences in cardiovascular mortality, hospitalization-free days, dyspnea, or global assessments over the 6 months of follow-up. The investigators found that compared to placebo, pimobendan improved exercise duration by 6% (p = 0. Other studies have demonstrated beneficial effects of pimobendan on reducing neurohormonal (norepinephrine, atrial,and brain natriuretic peptide) activation and on inhibiting the production of proinflammatory cytokines. Its metabolism is mainly hepatic, with a half-life ranging from 20-48 minutes in animal models. There were no effects on right atrial pressure, diastolic blood pressure, mean arterial pressure, or heart rate with any dose. There were no significant changes in brain natriuretic peptide, plasma renin activity, aldosterone, blood urea nitrogen, and creatinine. Dobutamine and milrinone can be used in combination with vasodilator drugs and diuretics to maximize hemodynamic benefit. Gene-based therapies, which perhaps offer the greatest opportunity to specifically target and enhance cardiac cellular function, are early in their development. The role of the antiplatelet and antithrombotic actions of these compounds remains somewhat controversial, although much recent evidence supports a true benefit for nitrate-induced decreases in platelet-thrombus activation. This drug, initially employed for anginal chest pain, became a mainstay of the homeopathic tradition in the early part of the twentieth century. Attenuation of nitrate effects, or nitrate tolerance, is the major obstacle to successful utilization of these drugs in clinical practice. In recent years, a wide variety of nitrate formulations and compounds has become available (Table 14-1), whereas some older nitrate compounds (eg, pentaerythritol tetranitrate) are no longer in use. Higher doses are often required in heart failure; Effect persists only while tablet intact in buccal cavity; Two daily doses 7 h apart; § Patch should be removed daily for 10­12 h. At high concentrations, nitrates dilate the smaller arteries, and at very high doses, nitrates can relax arterioles and the microcirculation. Systemic venous relaxation in the extremities and splanchnic circulation results in sequestration of the circulating blood volume away from the heart and lungs, with a fall in cardiac output. These drugs consistently lower pulmonary venous and pulmonary capillary pressure, which contributes significantly to their efficacy in heart failure as well as myocardial ischemia. Relaxation of the pulmonary arterial bed is beneficial to subjects with secondary pulmonary hypertension; nitrates do not generally have a useful role in primary pulmonary hypertension. Hemodynamic Correlates of Clinical Nitrate Efficacy Table 14-2 indicates the presumed mechanisms of action for the various clinical conditions for which these Table 14-2. The presumed paradigm is a major nitrate-induced decrease in cardiac work to match available coronary blood supply. However, in recent years much evidence and controversy have contributed to the view that the organic nitrates have important actions in increasing regional or nutrient coronary blood flow, particularly to areas of myocardial ischemia. In addition to epicardial coronary artery dilatation, other mechanisms may interact in a favorable fashion to alleviate or prevent ischemia by directly enhancing coronary blood supply to myocardium downstream from a fixed or dynamic coronary obstruction21,25 including (1) prevention or reversal of coronary artery vasoconstriction or spasm, (2) increased coronary collateral size and flow, (3) enhanced distal vessel and collateral caliber when constrictor forces predominate,26 (4) coronary atherosclerotic stenosis enlargement,27 and (5) improved coronary endothelial function3,18,28 (see Table 14-2). In the presence of even mild coronary atherosclerosis, the dilating actions of the endothelium are impaired in both the coronary and systemic circulations. Treatment and prophylaxis of anginal attacks as well as prevention of chest pain in chronic angina are the most important uses of these drugs. African-American Heart Failure Trial Investigators: Combination of isosobide dinitrate and hydralazine in blacks with heart failure. This agent has been successfully employed for post­coronary bypass patients with elevated blood pressure or hypertensive emergency. Oral nitrates, while used extensively in the early part of this century for hypertension, are not part of contemporary conventional therapy of systemic hypertension, in part because of the appearance of tolerance to the systolic pressure­lowering effects of these drugs. In intravenous, topical, or sublingual forms, they are useful as a treatment for acute pulmonary edema in conjunction with diuretics. With active treatment, there was a higher incidence of dizziness, nausea, vomiting, and hypotension compared to the placebo. There does not appear to be any difference in clinical efficacy among these compounds. Choice of formulation, dosage, use of a tolerance-avoidance regimen, and physician experience and bias are major factors influencing which nitrate is prescribed for which patient. Several studies confirm a true anti-ischemic action of these agents,79­81 which must be administered in an onoff fashion. Rebound angina and vasoconstriction are possible adverse effects of intermittent therapy. Suggestions for Nitrate Dosing It is important to start nitrate therapy with small doses and to carefully increase to a predetermined endpoint or maximally tolerated amount over time. Some individuals are extremely sensitive to organic nitrates; others experience few or no side effects. Many, if not most, patients are underdosed with longacting nitrates, at least with respect to clinical trial data. If the angina is well controlled with these relatively low doses, it is satisfactory to continue such a regimen. However, the physician should be sure that the more desirable clinical response has been achieved; if so, higher amounts of the nitrate should be tried. Often patients who are troubled with nitrate headaches with initial nitrate dosing can be effectively treated with analgesics (aspirin, acetaminophen) to control the headache symptoms, which usually decrease or disappear over time. Adverse Effects In addition to headache and hypotension-related dizziness or even syncope, nitrates can occasionally cause nausea. Rare cases of nitrate syncope have been reported, as have marked vasovagal responses and even atrioventricular block. Nitrates should also be used with greater care in patients receiving phosphodiesterase-5 inhibitors such as sildenafil because of the possibility of a major hypotensive effect with this combination. Headache, the most problematic symptom related to nitrate therapy,98 can be controlled in many patients. However, a possible 20% to 30% of individuals cannot tolerate long-acting nitrate therapy. Data confirm that endothelial vasodilator function is markedly impaired during nitrate tolerance. Older research suggested that nitrate tolerance is related to poor sulfhydryl or thiol group availability, plasma volume expansion, and/or neurohumoral activation of the renin-angiotensin system. Several studies suggest that antioxidants, such as hydralazine and vitamin C, can prevent or reverse nitrate tolerance;112­114,119 however, this approach remains as yet an unproven hypothesis. There is some evidence that not all organic nitrates have a comparable ability or potential to induce nitrate tolerance. Much of the available data suggest that during experimentally-induced nitrate tolerance, there is an enhanced Nitrate Tolerance Clearly, the most vexing issue regarding nitrate therapy is the attenuation of nitrate efficacy with repeated dosing. This subject has an enormous literature12­16,99-116 and continues to engender considerable controversy. However, almost all experts agree that tolerance will predictably appear when protolerant dosing regimens are utilized. Dozens of high-quality clinical and basic research studies underscore the magnitude of this problem. The rapid onset of tolerance can be substantiated after several repeated doses of oral or transdermal nitrate given with too short an interdose interval. Desensitization of soluble guanylate cyclase; impaired activity of the enzyme guanylate cyclase.

Pearl: the light reflex is not a reliable indicator of middle-ear or tympanic membrane disease erectile dysfunction drugs sales buy 120 mg silvitra free shipping. Newborns who fail newborn hearing screening should have followup evaluation by 3 months of age erectile dysfunction age statistics cheap 120 mg silvitra with visa, and those with identified hearing loss should have appropriate hearing rehabilitation and services by 6 months of age psychogenic erectile dysfunction icd-9 buy 120 mg silvitra mastercard. Despite the great success that has occurred with initial newborn hearing screening erectile dysfunction education cheap silvitra 120 mg online, half of those who fail screening do not receive follow-up testing erectile dysfunction and stress effective silvitra 120 mg. Children who are identified with hearing loss and receive intervention by 6 months of age usually have normal language development by 5 years; children who have delays in identification and intervention have difficulty catching up to their hearing peers. Because of the risk of delayed diagnosis in these children, in 2007, the Joint Committee on Infant Hearing updated its guidelines to improve identification of newborns at risk for late-onset hearing impairment (Box 1-1). The pediatrician plays an essential role in the ongoing screening for hearing loss. Pediatricians should be vigilant in screening for signs of developing hearing loss. They should provide parents with information on hearing, speech, and language milestones; identify and treat middle-ear disease; and provide ongoing developmental surveillance. Pediatricians should also be aware of and assess neonates for any of the risk factors for late-onset hearing loss. Neonatal intensive care of more than 5 days or any of the following regardless of length of stay: extracorporeal membrane oxygenation, assisted ventilation, exposure to ototoxic medications (gentamicin, tobramycin) or loop diuretics (furosemide/Lasix), and hyperbilirubinemia that requires exchange transfusion. In utero infections, such as cytomegalovirus, herpes, rubella, syphilis, and toxoplasmosis. Physical findings, such as white forelock, that are associated with a syndrome known to include a sensorineural or permanent conductive hearing loss. Syndromes associated with hearing loss or progressive or late-onset hearing loss, such as neurofibromatosis, osteopetrosis, and Usher syndrome; other frequently identified syndromes include Waardenburg, Alport, Pendred, and Jervell and Lange-Nielson. Neurodegenerative disorders, such as Hunter syndrome, or sensory motor neuropathies, such as Friedreich ataxia and Charcot-Marie-Tooth syndrome. Culture-positive postnatal infections associated with sensorineural hearing loss, including confirmed bacterial and viral (especially herpesviruses and varicella) meningitis. Head trauma, especially basal skull/temporal bone fracture that requires hospitalization. This test measures the function of the external auditory canal, tympanic membrane, middle ear, and outer hair cells of the cochlea but does not assess the inner hair cells of the cochlear or cochlear nerve. This assesses the entire hearing pathway with a sensitivity down to 30 dB (normal hearing is considered 20 dB). Neither determine the degree of hearing loss and both can miss mild hearing loss (<30 dB). Auditory neuropathy/dyssynchrony is a disorder in which sound enters the inner ear normally, but the transmission of sound 12 Chapter 1: Neonatal Hearing Screening, Hearing Loss, and Treatment for Hearing Loss via the cochlear nerve to the brain is abnormal. Pearl: All newborns should be screened for hearing loss by discharge or 1 month of age; those who fail newborn hearing screening should have follow-up evaluation by 3 months of age; and those with identified hearing loss should have appropriate hearing rehabilitation and services by 6 months of age. Auditory brain stem response is an electrophysiologic measurement of the function of the entire hearing pathway, including the brain stem. It is performed by placing earphones or probes in the ears, which give clicks and tones, and electrodes on the head that measure the waveform response to the sounds given. Auditory brain stem response can be performed in sleeping babies or with sedation. The probe also contains a microphone that detects acoustic signals generated by the cochlea in response to sound. Otoacoustic emissions do not quantify the degree of hearing loss and do not assess the function of the auditory nerve or brain stem. In addition, middle ear or tympanic pathology will affect the accuracy of this test. Hearing cannot be confirmed until the child is old enough to undergo audiometric testing. Children vary in their ability to cooperate with behavioral audiometric testing, and various tests exist for different ages. Air conduction transmits sound through the ear canal to the tympanic membrane, ossicles, and cochlea. Measurements of these allows the audiologist to determine if hearing loss is conductive (caused by pathology in the ear canal, tympanic membrane, middle ear, or ossicles) or sensorineural (caused by pathology of the cochlea or eighth nerve). Visual Reinforcement Audiometry Infants as young as 6 months may be able to provide behavioral hearing responses. Some children may tolerate wearing earphones and individual ear hearing data can be obtained. Most young children will not wear earphones and the hearing is assessed in "the sound field," meaning that only the hearing of both ears together can be measured. This allows for accurate measurement of hearing in only the ear that hears better, so unilateral hearing loss cannot be ruled out. Children of this age can usually wear headphones and individual ear hearing levels can be obtained. Conventional Audiometry Children older than 4 years can undergo audiometry testing in the same way as adults-by wearing headphones and raising their hand when they hear auditory stimuli. Tympanometry Tympanometry assesses the mobility of the tympanic membrane by creating positive and negative pressure in the ear canal. Tympanometry results can provide information about the integrity of the tympanic membrane and the condition of the middle ear and ossicles. The otolaryngologist will review the history and perform a thorough physical examination, as outlined previously. In addition, the specialist will counsel the family on the consequences of hearing loss and will pursue diagnostic evaluations to potentially determine the cause. Cost-benefit analyses have suggested that these studies 15 Pediatric Otolaryngology should be limited to selective ordering based on a thorough history and physical examination and perhaps only after other high-yield tests have been performed. Almost certainly, the best approach to testing is to engage in an informed discussion with parents or caregivers to come to a mutually acceptable decision about which tests to perform. Children who have ear anomalies (including those with just preauricular pits or cup ears) and also have hearing loss, dysmorphic features, a family history of deafness, or a maternal history of gestational diabetes or diabetes mellitus, should undergo a renal ultrasound. In addition, there are many other gene mutations associated 16 Chapter 1: Neonatal Hearing Screening, Hearing Loss, and Treatment for Hearing Loss with syndromic and non-syndromic hearing loss, the clinical availability of which is constantly evolving. The interpretation of genetic tests and the understanding of the ramifications of the diagnosis of a syndrome are complex and require the expertise of genetic counselors. A genetics team should always be engaged when evaluating for the presence of a syndrome and are also highly useful for pretest and posttest counseling about genetic testing results. Syndromic children are especially likely to have ocular anomalies, and all should undergo evaluation by an ophthalmologist. In addition, non-syndromic children with hearing loss are at particular risk for decreased learning and function if they also have visual impairment; thus, it would be wise to ensure that their vision is fully intact. Pearl: Many otolaryngologists are opting for sequential testing of the highest yield tests to limit radiation and reduce unnecessary evaluations. Hearing loss can also be defined as stable or progressive, congenital or delayed onset, and genetic or nongenetic. Therefore, most children with genetic loss are born to parents with normal hearing. The remaining distribution of non-syndromic hereditary hearing loss is 20% autosomal dominant, 2% to 5% X-linked, and 1% mitochondrial. Audiogram of Familiar Sounds Reprinted with permission from American Academy of Audiology. Hearing loss is usually congenital and severe to profound, but milder losses and progressive loss are possible. They should also be counseled to avoid head trauma, wear protective helmets when engaged in cycling or skiing, and avoid activities such as contact sports and scuba diving. Vaccinations against common causes of congenital hearing loss have nearly eliminated etiologies such as rubella. Antivirals given in this critical period may prevent the development or limit progression of hearing loss. In the perinatal period, the most common causes of acquired hearing loss are related to other postnatal morbidities. Many of the risk factors, such as low Apgar scores and prematurity, are most likely due to hypoxemic injury to the inner ear and cochlear nerve. These children are at particular risk for auditory neuropathy/dyssynchrony and require continued surveillance for progressive loss. Pearl: Identifying the cause of hearing loss can help families process the diagnosis and make treatment decisions. Often considerable time delay occurs between identification of a hearing loss and fitting of hearing aids. This can be because of issues with cost, access to audiologic services, or parental concern about the use of hearing aids. Clinicians should emphasize to parents the extreme importance of children with hearing impairment to wear hearing aids and that this is essential for excellent speech and language development and good school performance. Social recognition by peers of "differentness" does not usually occur until 5 or 6 years of age; this may reassure some parents about the appearance of wearing hearing aids. As children get older, they may decide not to wear their aids for various reasons, including lack of perceived benefit and social issues. Clinicians and caregivers should respect the concerns of these children, while at the same time continuing to assess whether they are having difficulties in school or communication by not wearing the aids. Hearing aids are fitted by creating a properly sized mold for the external ear and canal. The amplification is adjusted to optimize hearing while avoiding pain from sound pressure on the tympanic membrane. Adolescents whose ears are fully grown may use smaller aids that are partly or completely in the ear canal, but these cost more, cannot be coupled to other devices, and are more easily damaged. Some children do not tolerate this because they do not wish to wear an aid in the normal-hearing ear. In addition, some children who have chronic ear drainage that cannot be treated by surgery cannot wear aids in the ear. Sound is transmitted through the bone directly to the cochlea, bypassing the external and middle ear. Until then, they can wear a headband (soft band) that holds the sound processor firmly against the skull. Some children prefer the soft band to surgery and opt to continue to use it instead of undergoing surgery, though most find the hearing quality better with the bone-anchored hearing aid. New, surgically implantable bone conducting hearing aids avoid the visible and sometimes troublesome titanium screw abutment on the skull. Many schools offer brief sessions 1 or 2 times per week, but children with significant delays may require more intensive therapy outside of school. Children with hearing impairment should always be supplied with an individual education plan to ensure they are receiving the services they require. Pearl: Early intervention and multidisciplinary collaboration are necessary for the best outcomes for children with hearing impairment. Numerous studies have shown a clear benefit of implantation over amplification or other modes of communication. Children who experience delays in receiving an implant beyond their first birthday are at increasing risk for poor speech and language development, whereas children who receive implants at or near 12 months of age have the potential to function at the level of their normal-hearing peers. Children who have developed late-onset hearing loss after the development of language (postlingually deaf) are also excellent candidates. Older children will be evaluated by audiometry as well as several more specific tests that assess the development of speech and language. This serves to determine if they may have suitable benefit from hearing aids and also to assess if they and their parents will be compliant with wearing an aid device regularly. Children with abnormalities of the inner ear are still candidates for implantation, but modifications in surgical technique and expectations of outcome by parents may be necessary. While many children have excellent outcomes, it is not possible beforehand to predict how someone will perform with an implant. Children with developmental delay, autism spectrum disorders, or other cognitive issues may not perform as well. This does not preclude them from being implanted, but it is important for parents to tailor their expectations. In addition, families must understand that the aural rehabilitation following implantation is intensive and requires a longterm commitment. The cochlear implant team should determine that adequate resources will be available to have the maximal benefit of the implant. Educational programs for the hearing impaired are varied in their emphasis and quality, and children undergoing implantation should be in programs that promote listening and speaking instead of signed communication, as their ultimate outcome is considerably dependent on the quality of these programs. Continuing assessment and dialogue should occur among audiologists, otolaryngologists, speech pathologists, school, and family to ensure a maximal benefit from the implant. In general, children who have or are at risk for speech or cognitive delay should have tubes placed earlier, while those who do not can be observed longer. Children who use cotton-tipped applicators to clean their ear are at risk for cerumen impaction, as well as retaining part of the applicator in their ear. Prognosis Immunizations and antibiotics have contributed substantially in decreasing many causes of pediatric hearing loss. Prior to vaccines, mumps and rubella were leading causes of pediatric hearing loss. The proportion of hearing loss due to other causes has shifted to genetic mutations and complications in the neonatal period. Even children with mild hearing loss are at risk for delays in speech and language development. In particular they may have difficulty acquiring new words and may require visual and auditory input to develop language at the rate of their peers. The more severe the hearing loss, the greater the risk for deficient speech acquisition and poor academic performance. Infants with severe to profound loss will develop no spoken language at all without amplification or cochlear implantation.

Order 120 mg silvitra otc. Can Erectile Dysfunction Be Cured - Curing ED (Impotence) is Not That Hard.

References

• Panteli C: New insights into the pathogenesis of infantile pyloric stenosis. Pediatr Surg Int 25:1043, 2009.
• Suchting S, Freitas C, le Noble F, et al: The Notch ligand delta-like 4 negatively regulates endothelial tip cell formation and vessel branching, Proc Natl Acad Sci U S A 104(9): 3225-3230, 2007.
• Desormeaux AJ, Hunt RP. The Endoscope, and Its Application to the Diagnosis and Treatment of Affections of the Genito-Urinary Passages. Lessons Given at Necker Hospital. Chicago, IL: Robert Fergus' Sons; 1867.
• Moncada S, Higgs A: The l-arginine-nitric oxide pathway, N Engl J Med 329(27):2002n2012, 1993.
• Ward VMM, Selvadurai D: A magnetic nasal attraction. J Accid Emerg Med 17:53, 2000.
• Marinkovic S, Kovacevic M, Milisavljevic M. Hypoplasia of the proximal segment of the anterior cerebral artery. Anat Anz 1989;168:145.
• Kimura K, Minematsu K, Wada K, et al. Lesions visualized by contrast-enhanced magnetic resonance imaging in transient ischemic attacks. J Neurol Sci 2000;173:103-8.
• Wattanathum A, Chaoprasong C, Nunthapisud P, et al. Community-acquired pneumonia in southeast Asia: the microbial differences between ambulatory and hospitalized patients. Chest 2003;123:1512-9.